Jazz Pharmaceuticals(JAZZ) - 2025 Q4 - Annual Results
Jazz Pharmaceuticals(US:JAZZ)2026-01-12 14:01Revenue Guidance - Jazz Pharmaceuticals expects to meet its previously announced total revenue guidance range for the year ended December 31, 2025[4] - The company will provide specific revenue expectations for its products Xywav, Epidiolex, and Modeyso for the year ended December 31, 2025[4] Corporate Events - The corporate overview and financial update will be presented at the J.P. Morgan Healthcare Conference on January 13, 2026[4]